DBC1在卵巢癌中的表达及临床意义  

The expression and clinical significance of DBC1 in ovarian cancer

作　　者：林丽[1] 吴洪英[1] 孙春霞[1] 

机构地区：[1]聊城市人民医院妇产科,山东聊城252000

出　　处：《现代肿瘤医学》2016年第13期2139-2141,共3页Journal of Modern Oncology

摘　　要：目的:探讨乳腺癌缺失基因1(DBC1)在卵巢癌组织中的表达及与临床参数的相关性。方法:收集山东省聊城市人民医院手术切除的上皮性卵巢癌组织121例、交界性上皮性肿瘤组织40例和良性囊腺瘤组织55例,所有患者术前均未进行放疗、化疗等治疗。采用免疫组化技术检测DBC1在组织中的表达情况,并分析其与临床病理特征的相关性。结果:DBC1的阳性表达在卵巢癌组织中明显高于交界性囊腺瘤和良性囊腺瘤(P=0.001,P=0.000),其表达水平与FIGO分期、分化程度及预后密切相关(P=0.033,P=0.022,P=0.037)。结论:DBC1在卵巢癌中可作为肿瘤促进因子发挥作用,并且与预后密切相关,可作为卵巢癌的肿瘤标志物之一。Objective：To explore the expression and significance of DBC1 in ovarian cancer tissues.Methods：All 121 cases of ovarian cancer tissues,40 cases of borderline epithelial neoplasms and 55 cases of benign cystadenoma were collected from patients who underwent initial hysterectomy.All patients were not treated with radiotherapy and chemotherapy before surgery.The expression of DBC1 protein was detected using immunohistochemistry.Its correlation with clinicopathological features was analyzed.Results：Expressions of DBC1 in ovarian cancer was significantly higher than borderline epithelial neoplasms and benign cystadenoma（P =0.001,P =0.000）,it was closely correlated with differentiation,FIGO stages and prognosis（P =0.033,P =0.022,P =0.037）.Conclusion：DBC1 acts as a tumor promoter in ovarian cancer,and is associated with prognosis.It canbe a tumor marker.

关 键 词：DBC1 卵巢癌 免疫组织化学技术 预后 肿瘤标志物 

分 类 号：R737.31[医药卫生—肿瘤]